Effect of Symbiotic on Non-Alcoholic Fatty Liver Disease (NAFLD)
Not Applicable
- Conditions
- AFLD.Fatty (change of) liver
- Registration Number
- IRCT2013122811763N15
- Lead Sponsor
- Vice chancellor for research, Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
aged 18-60 years; confirmation of NAFLD with Ultrasonography and increased levels of Ast and Alt; desire to participate in the study. Exclusion criteria: organ transplantation; presence of pregnancy and lactation; suffering from Wilson disease; chronic liver diseases unless NAFLD; Diabetes Mellitus; Cancer; antibiotics therapy; Receiving Oral Contraceptive Pill (OCP); drugs such as corticosteroids, Amiodarone, Tamoxifen, Cyclins, Perhexiline, Methotrexate and Hydralazine; Receiving of vitamin-mineral and omega-3 Supplements during the study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fatty liver grade. Timepoint: before and after the intervention. Method of measurement: Ultrasonography.;Alt_Ast. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (blood tests).;Lipid profiles. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (enzymatic).;Inflammatory markers. Timepoint: before and after the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA).;Body composition. Timepoint: before and after the intervention. Method of measurement: Bioelectrical Impedance Assessment.
- Secondary Outcome Measures
Name Time Method